Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 1, 2003, Pages 71-77

  Watanabe, Rika ^a   Wada, Hideo ^b   Yamamuro, Miho ^a   Inoue, Akiko ^a   Watanabe, Masato ^a   Kumeda, Kousuke ^c   Sakakura, Miho ^a   Okugawa, Yoshinaga ^a   Nakasaki, Takahiro ^a   Deguchi, Hiroshi ^a   Gabazza, Esteban C ^a   Mori, Yoshitaka ^a   Nishikawa, Masakatsu ^a   Nobori, Tutomu ^b   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Clinical Laboratory ^*  (Japan)

^c Kaketsuken   (Japan)

Author keywords

DIC; Good outcome; Molecular marker; Poor outcome; Prognosis

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; GABEXATE MESILATE; HEPARIN; MOLECULAR MARKER; PLASMIN; PLASMIN INHIBITOR; THROMBOMODULIN; THROMBOPLASTIN;

ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RESPONSE; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN METABOLISM; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTHROMBIN TIME; SCORING SYSTEM;

EID: 0037221367     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900110     Document Type: Article

References (24)

1. Bick RL. Disseminated intravascular coagulation and related syndromes: A clinical review. Semin Thromb Hemost 1998;14:299.
2. Müller-Berghaus G. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semin Thromb Hemost 1989;15:58.
3. Ohno H, Kosaki G, Kambayashi J, et al. FOY; [ethyl p-(6guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980;19:579.
4. Ohno H, Kambayashi J, Chang SW, et al. FOY; [ethyl p(6-guanidinohexanoxyloxy) benzoate] methanesulfonate as a serine protease inhibitor. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981;24:445.
5. Sakuragawa N, Hasegawa H, Maki M, et al. Clinical evaluation of low molecular weight heparin (FR-860) on disseminated intravascular coagulation (DIC): A multicenter cooperative double-blind trial in comparison with heparin. Thromb Res 1993;72:475.
6. Larcan A, Lambert H, Gerard A. Treatment of consumption coagulopathies. Masson Publishing, Paris, France; 1987:165.
7. Wada H, Wakita Y, Nakase T, et al. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Thromb Hemost 1995;74:848.
8. Pelzer H, Schwarz A, Heinburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1987;59:101.
9. Mimuro J, Koike Y, Sumi Y, et al. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor. Blood 1987;59:101.
10. Rylatt DB, Blake AS, Cottis LE, et al. An immunoassay for human D-dimer using monoclonal antibodies. Thromb Res 1983;31:767.
11. Bredbacka S, Blomback M, Wiman B. Soluble fibrin: A predictor for the development and outcome of multiple organ failure. Am J Hematol 1994;46:289.
12. Kienast J, Thompson SG, Raskino C, et al. Prothrombin fragment 1+2 and thrombin-antithrombin III complexes in patients with angina pectoris: Relations to the presence and severity of coronary atherosclerosis. Thromb Haemost 1993;70:550.
13. Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombocytopenic purpura patients with severe vascular injuries. Am J Hematol 1998;58:189.
14. Wada H, Sakuragawa N, Mori Y, et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am J Hematol 1999;60:273.
15. Kobayashi N, Maegawa K, Takada M, et al. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haematol 1987;49:265.
16. Wada H, Minamikawa K, Wakita Y, et al. Femostatic study before onset of disseminated intravascular coagulation. Am J Hematol 1994;43:265.
17. Wada H, Tomeoku M, Deguchi A, et al. Anticoagulant activity in cell homogenate of aduIt T cell leukemia. Thromb Haemost 1988;59:179.
18. Yamamuro M, Wada H, Kumeda K, et al. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation. Blood Coag Fibrinol 1998;9:491.
19. Poller L. A simple nomogram for the derivation of internal normalized ratios for the standardization of prothrombin times. Thromb Haemost 1988;60:18.
20. Loeliger EA, van den Besselaar AM, Lewis SM. Reliability and clinical impact of normalization of the prothrombin times in oral anticoagulant control. Thromb Haemost 1985;53:148.
21. Wada H, Wakita Y, Nakase T, et al. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;51:255.
22. Hoppensteadt DA, Walenga JM, Fasanella A, et al. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175.
23. Wada H, Wakita Y, Shiku H. Tissue factor expression in endothelial cells in health and disease. Blood Coag Fibrinolysis 1995;6:s23.
24. Shimura M, Wada H, Nakasaki T, et al. Increased truncated form of plasma tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol 1996;60:94.